Perspective Therapeutics, Inc.
CATX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000728387
In the last 90 days, Perspective Therapeutics, Inc. insiders filed 1 open-market purchase and 5 sales; 131 institutions reported holding it in 13F filings for Q2 2026, worth $297.6M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:12 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K/A | 10-K | 10-KT | 10-K |
| Reported | Jan 9, 2026 | Jan 13, 2025 | Jan 17, 2024 | Feb 16, 2023 | Sep 28, 2022 |
| Revenue | – | – | $1.43M | – | $10.8M |
| Cost of revenue | – | – | – | – | $6.18M |
| Gross profit | – | – | $1.43M | – | $4.62M |
| Operating expenses | $114.4M | $92.3M | $42.4M | – | $12.0M |
| Research and development | $84.2M | $41.6M | $21.3M | – | $2.58M |
| Selling, general and administrative | $30.2M | $26.6M | $21.1M | – | $6.62M |
| Operating income | -$113.6M | -$90.9M | -$40.9M | – | -$7.39M |
| Interest expense | – | – | $84.0K | – | – |
| Income tax | -$793.0K | -$2.10M | -$2.65M | – | $0 |
| Net income | -$103.1M | -$79.3M | -$46.5M | – | -$7.27M |
| EPS, basic | $-1.40 | $-1.23 | $-0.17 | – | $-0.05 |
| EPS, diluted | $-1.40 | $-1.23 | – | – | – |
| Weighted shares, basic | 73.8M | 64.4M | 267.6M | – | 142.0M |
| Weighted shares, diluted | 73.8M | 64.4M | – | – | – |
| Margins and growth | |||||
| Gross margin | – | – | 100.0% | – | 42.8% |
| Operating margin | – | – | -2855.0% | – | -68.5% |
| Net margin | – | – | -3243.2% | – | -67.4% |
| Revenue growth, year over year | – | – | – | – | +7.4% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K/A | 10-K | 10-KT | 10-K |
| Reported | Jan 9, 2026 | Jan 13, 2025 | Jan 17, 2024 | Feb 16, 2023 | Sep 28, 2022 |
| Cash and equivalents | $30.6M | $61.6M | $9.24M | $21.0M | $55.9M |
| Short-term investments | $114.1M | $165.3M | $0 | $22.8M | – |
| Accounts receivable | $6.00K | $116.0K | $1.17M | $1.36M | $1.61M |
| Inventory | – | – | – | $1.41M | $1.40M |
| Total current assets | $148.4M | $231.2M | $16.8M | $53.2M | $59.3M |
| Property, plant and equipment | $76.6M | $57.3M | $5.58M | $1.68M | $1.98M |
| Goodwill | – | $0 | $24.1M | – | – |
| Intangible assets | $362.0K | $279.0K | $354.0K | $86.0K | $107.0K |
| Total assets | $267.0M | $341.1M | $97.9M | $58.1M | $64.4M |
| Total current liabilities | $28.7M | $18.2M | $15.7M | $2.68M | $2.27M |
| Long-term debt | $1.63M | $1.68M | $1.73M | – | – |
| Total liabilities | $59.9M | $50.4M | $22.7M | $3.45M | $3.16M |
| Shareholders' equity | $207.0M | $290.7M | $75.2M | $54.6M | $61.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Jun 30, 2022 |
| Filing | 10-K | 10-K/A | 10-K | 10-KT | 10-K |
| Reported | Jan 9, 2026 | Jan 13, 2025 | Jan 17, 2024 | Feb 16, 2023 | Sep 28, 2022 |
| Operating cash flow | -$82.5M | -$18.3M | -$36.9M | – | -$7.71M |
| Capital expenditures | $12.7M | $54.4M | $1.07M | – | $266.0K |
| Free cash flow | -$95.2M | -$72.7M | -$38.0M | – | -$7.98M |
| Depreciation and amortization | $3.25M | $2.31M | – | – | – |
| Stock-based compensation | $8.97M | $5.39M | $3.74M | – | $1.09M |
| Investing cash flow | $41.2M | -$218.9M | $24.4M | – | -$284.0K |
| Financing cash flow | $10.3M | $289.4M | $785.0K | – | $56.0K |
| Net change in cash | -$31.0M | $52.2M | -$11.8M | – | -$7.94M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | – | 260.7% | – | 10.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 4, 2026 | 120.8M | +62.4% | SEC |
| Aug 5, 2026 | 114.2M | +53.7% | SEC |
| May 6, 2026 | 114.0M | +53.6% | SEC |
| Mar 12, 2026 | 113.9M | +53.9% | SEC |
| Nov 6, 2025 | 74.3M | +10.0% | SEC |
| Aug 11, 2025 | 74.3M | +10.1% | SEC |
| May 7, 2025 | 74.2M | −88.1% | SEC |
| Mar 21, 2025 | 74.1M | −87.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.